Home Research Area Other solid tumors, bone and blood cancers

Other solid tumors, bone and blood cancers

Telix’s is exploring the potential utility of targeted radiation in a range of difficult to treat musculoskeletal and blood cancers, including soft tissue sarcoma (STS), bone cancer, acute myeloid leukemia (AML), multiple myeloma (MM), systemic amyloid light chain amyloidosis (SALA) and pediatric leukemia.

.

Soft tissue sarcoma (STS)

Soft tissue sarcoma is a complex disease that encompasses a diverse group of relatively rare cancers. In late-stage disease, the prognosis for these patients remains poor, with treated patients with metastatic disease having a median overall survival of around 12–18 months.

Bone Cancer

Bone pain is frequently experienced by cancer patients with metastatic disease, especially those with prostate, lung and breast cancers. In these cases, disease management often focuses on quality-of-life palliative care.

Bone Marrow Conditioning

Prior to undergoing hematopoietic stem cell transplantation (HSCT) for the treatment of blood cancers, patients undergo a bone marrow conditioning (BMC) treatment. The current standard of care typically requires BMC with multi-drug chemotherapy regimens. However, these regimens are highly toxic, and patients may not tolerate treatment. This creates an important unmet medical need for more tolerable BMC regimens.

.

Our musculoskeletal cancers portfolio
Our musculoskeletal cancers trials

Our musculoskeletal portfolio

  • Therapeutics

    • TLX66 (90Y-besilesomab)

      Telix’s investigational therapy granted orphan drug designation (ODD) status in Europe and the U.S. for bone marrow conditioning for hematopoietic stem cell transplantation (HSCT), a broad clinical indication with applicability to many different diseases. TLX66 has been evaluated in approximately 100 patients, with promising results both as a monotherapy and in combination with low-dose chemotherapy conditioning regimes.

    • TLX300 (Tx-olaratumab)

      Telix’s investigational therapy being developed for the treatment of patients with advanced or metastatic STS, administered in combination with doxorubicin. We have completed pre-clinical validation for this asset and the ZOLAR trial is recruiting patients in Australia. We intend to develop the therapeutic application of TLX300 for the treatment of STS based on a theranostic approach.

    • TLX090 (153Sm-DOTMP)

      Telix’s novel investigational kit-based bone-seeking targeted radiopharmaceutical that uses a “next-generation” chelating agent to deliver a proprietary formulation of Samarium-153. TLX090 is highly aligned with Telix’s existing therapeutic focus areas of prostate cancer, glioma and sarcoma, and has been granted orphan drug and rare pediatric disease designations by the FDA for the treatment of osteosarcoma.

  • Diagnostics

    • TLX66-CDx (99mTc-besilesomab)

      Telix’s imaging agent against CD66, is an approved product (marketed as Scintimun®) for imaging osteomyelitis (bone infection) in approximately 30 countries. We have identified significant potential to expand clinical utility, including as a companion patient selection and safety assessment tool for TLX66.

Active Trials

Active trials for Musculoskeletal Cancers

View all trials

SOLACE
Recruiting
US , 
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
Find out more

ZOLAR
Recruiting
Australia , 
Phase 1 Study of 89Zr-labelled olaratumab (TLX300-CDx) in Soft Tissue Sarcoma (STS)
Find out more